Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: Fitzhughlaw who wrote (878)	2/19/2025 5:10:01 PM
From: TinfoilHat	4 Recommendations Recommended By bobbseytwins2001 Davidoff rodneyh07 sukit Respond to of 1232

This BCG news is a big deal! Academic centers don't have issues getting BCG, it's the smaller urology offices that have been needing to refer out to academic sites if unable to get, and keep in mind that urologists make money from in-office procedures. They love BCG! Also, urologists don't get into the field for the love of the game. Maybe a handful are wanting proximity to old man dik n balz, but the vast majority chose this field to make MONEY! Urologists will be ringing IBRX for access to BCG to keep those infusions in-house, and can now also bill for Anktiva which is win win for patients too. We have momentum, technicals are shaping up to be good too. C'mon short squeeze!